NCT00778297 - Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine | Biotech Hunter

Enrollment

234

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

May 31, 2008

Conditions

Influenza

Interventions

BIOLOGICAL

Vaccination with FluvalAB FL-K-004 trivalent flu vaccine

Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).

BIOLOGICAL

Vaccination with FluvalAB trivalent influenza vaccine

Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).

Trial Locations (1)

Pilisvörösvár District Doctor's Office, Pilisvörösvár